Home › Research › Clinical safety
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup
Reisa Anne Sperling, Clifford R. Jack, Sandra E. Black, Matthew P. Frosch, Steven Mark Greenberg, Bradley T. Hyman, Philip Scheltens, María C. Carrillo, William H. Thies, Martin M. Bednar, Ronald S. Black, H. Robert Brashear, Michael Grundman, Eric Siemers, Howard Feldman, Rachel J. Schindler. Alzheimer s & Dementia, 2011-07-01
Topic: Amyloid, tau and blood-test diagnosis
The Alzheimer's Association Research Roundtable convened a working group to review data on amyloid imaging related abnormalities (ARIA) in response to concerns raised by the Food and Drug Administration. ARIA includes signal hyperintensities thought to represent vasogenic edema and/or sulcal effusion (ARIA-E) and signal hypointensities thought to represent hemosiderin deposits (ARIA-H). The workgroup proposed recommendations for detecting and monitoring ARIA in Alzheimer's disease clinical trials and provided directions for future research.
Key findings
- Amyloid imaging related abnormalities (ARIA) have now been reported in clinical trials with multiple therapeutic avenues to lower amyloid-β burden in Alzheimer's disease (AD).
- The spectrum of ARIA includes signal hyperintensities on fluid attenuation inversion recoverysequences thought to represent "vasogenic edema" and/or sulcal effusion (ARIA-E), as well as signal hypointensities on GRE/T2* thought to represent hemosiderin deposits (ARIA-H), including microhemorrhage and superficial siderosis.
- The etiology of ARIA remains unclear but the prevailing data support vascular amyloid as a common pathophysiological mechanism leading to increased vascular permeability.
Why it matters
Gives recommendations from an Alzheimer's Association Research Roundtable workgroup on amyloid-related imaging abnormalities in trials of amyloid-modifying therapies.
How this study scored 55/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on strength of evidence, so that was left out: it earned 52 of the 95 points we could judge it on, which is 55 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | — / 5 | No evidence rating recorded — left out of this score |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2011 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 852 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 50.1 citations a year over 17 year(s) since 2011 |
| Impact for its field and year | 5 / 6 | Cited 25.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 4 / 4 | Cited 305 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Rachel J. Schindler: h-index 27 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multi-centre collaboration | 3 / 3 | OpenAlex lists 13 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 21784348) |
| Free to read | 2 / 2 | Free to read |
| Points | 52 / 95 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 52 of the 95 points we could judge it on is 55 out of 100. |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.jalz.2011.05.2351
- PubMed: 21784348
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 16 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
APA 7th
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., et al. (2011). Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2011.05.2351
Vancouver
Sperling RA, Jack CR, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimer s & Dementia. 2011. doi:10.1016/j.jalz.2011.05.2351. PMID: 21784348.
BibTeX
@article{sperling2011-21784348,
author = {Sperling, Reisa Anne and Jack, Clifford R. and Black, Sandra E. and Frosch, Matthew P. and Greenberg, Steven Mark and Hyman, Bradley T. and Scheltens, Philip and Carrillo, María C. and Thies, William H. and Bednar, Martin M. and Black, Ronald S. and Brashear, H. Robert and Grundman, Michael and Siemers, Eric and Feldman, Howard and Schindler, Rachel J.},
title = {{Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup}},
journal = {Alzheimer s \& Dementia},
year = {2011},
doi = {10.1016/j.jalz.2011.05.2351},
pmid = {21784348},
url = {https://doi.org/10.1016/j.jalz.2011.05.2351}
}
Related studies in Clinical safety
Also tagged “classification”
835 studies in the library carry the topic tag “classification”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 835 tagged studies.